Research Costs Investigated: A Study Into the Budgets of Dutch Publicly Funded Drug-Related Research by Asselt, T. (Thea) van et al.
ORIGINAL RESEARCH ARTICLE
Research Costs Investigated: A Study Into the Budgets of Dutch
Publicly Funded Drug-Related Research
Thea van Asselt1,2 • Bram Ramaekers3 • Isaac Corro Ramos4 •
Manuela Joore3 • Maiwenn Al5 • Ivonne Lesman-Leegte1 • Maarten Postma1,2 •
Pepijn Vemer1,2 • Talitha Feenstra1,6
 The Author(s) 2017. This article is an open access publication
Abstract
Background The costs of performing research are an
important input in value of information (VOI) analyses but
are difficult to assess.
Objective The aim of this study was to investigate the
costs of research, serving two purposes: (1) estimating
research costs for use in VOI analyses; and (2) developing
a costing tool to support reviewers of grant proposals in
assessing whether the proposed budget is realistic.
Methods For granted study proposals from the Netherlands
Organization for Health Research and Development
(ZonMw), type of study, potential cost drivers, proposed
budget, and general characteristics were extracted.
Regression analysis was conducted in an attempt to
generate a ‘predicted budget’ for certain combinations of
cost drivers, for implementation in the costing tool.
Results Of 133 drug-related research grant proposals, 74
were included for complete data extraction. Because an
association between cost drivers and budgets was not
confirmed, we could not generate a predicted budget based
on regression analysis, but only historic reference budgets
given certain study characteristics. The costing tool was
designed accordingly, i.e. with given selection criteria the
tool returns the range of budgets in comparable studies.
This range can be used in VOI analysis to estimate whether
the expected net benefit of sampling will be positive to
decide upon the net value of future research.
Conclusion The absence of association between study
characteristics and budgets may indicate inconsistencies in
the budgeting or granting process. Nonetheless, the tool
generates useful information on historical budgets, and the
option to formally relate VOI to budgets. To our knowl-
edge, this is the first attempt at creating such a tool, which
can be complemented with new studies being granted,
enlarging the underlying database and keeping estimates up
to date.
Key Points for Decision Makers
Predicting budgets from study characteristics proves
to be difficult.
We designed a costing tool that, given certain details
for a study, provides a range of historical budgets for
comparable studies.
This estimate can be used for VOI analysis, as well
as for appraising budgets in grant proposals.
Electronic supplementary material The online version of this
article (doi:10.1007/s40273-017-0572-7) contains supplementary
material, which is available to authorized users.
& Thea van Asselt
a.d.i.van.asselt@umcg.nl
1 Department of Epidemiology, University Medical Centre
Groningen, University of Groningen, Groningen, The
Netherlands
2 Department of Pharmacy, University of Groningen,
Groningen, The Netherlands
3 Department KEMTA, Maastricht University Medical Centre,
Maastricht University, Maastricht, The Netherlands
4 Institute for Medical Technology Assessment, Erasmus
University, Rotterdam, The Netherlands
5 Erasmus School of Health Policy and Management, Erasmus
University, Rotterdam, The Netherlands
6 Centre for Nutrition, Prevention and Health Services, RIVM,
Bilthoven, The Netherlands
PharmacoEconomics
DOI 10.1007/s40273-017-0572-7
1 Introduction
Evidence on cost effectiveness is increasingly required and
is used for decisions to adopt or reimburse new health
technologies. The analytical framework that is set up to
produce this evidence also facilitates value of information
(VOI) analysis, which aims to assess whether further
research is worthwhile [1]. Moreover, VOI may nowadays
be required with a new drugs submission, as, for example,
in The Netherlands [2]. If the expected value of perfect
information (EVPI) is non-negligible, an important step is
the estimation of the expected net benefit of sampling
(ENBS): the comparison of the costs of research to its
added value. For this comparison, an accurate estimate of
the costs of research is essential; however, currently there
is no information available that can serve as a starting point
for such estimates. From a consistency viewpoint, it would
be desirable that these cost estimates were standardized
within each decision-making jurisdiction. Additionally, for
many grant programs, such as from the Netherlands
Organization for Health Research and Development
(ZonMw), reviewers need to assess the reasonableness of
the proposed budget. Insight into the costs of research helps
reviewers in this task. Finally, for both purposes, it would
be valuable to enable easy access to the information by way
of an electronic costing tool.
While some studies investigated the costs of randomized
controlled trials (RCTs) [3–8] (often in pharmaceutical
companies’ settings), little research has been done into the
costs of other types of medical or epidemiological studies,
such as cohort studies or literature reviews. Furthermore,
existing studies used expert opinions or estimated costs of
hypothetical projects, rather than actual observational data,
and were aimed at, for instance, justifying the fee per
patient received by the physician by demonstrating that
treatment of participants in a trial was more expensive than
treatment of non-participants. In addition, studies focusing
on RCTs in companies’ settings might differ considerably
from costs in an academic setting. Furthermore, studies
concerning VOI analysis usually made rather simplistic
assumptions about costs of research [9]. In contrast, recent
publications on the use of VOI in practice do not even
mention the issue of costing research, focusing more on the
technicalities of VOI [10–12]. This shows that costing of
various types of research is a neglected issue in VOI
analysis, while it is indispensable to actual calculations of
the Expected Value of Sampling Information and ENBS.
This paper aims to provide a pragmatic overview of the
costs of several types of research. This overview enables
two distinct purposes: (1) to provide an estimate of
research costs of various study types for use in VOI; and
(2) to develop an electronic costing tool that can be used to
support reviewers of grant proposals in the task of evalu-
ating the budget of the proposed project. Of note, results
from our tool form part of what is required for a VOI
analysis. Other elements of costs, such as opportunity costs
falling on individuals enrolled in the less optimal treatment
arm while performing the research, should be added
separately.
2 Methods
2.1 Dataset
Grant proposals regarding drug-related health services
research were obtained mainly from the ‘Goed Gebruik
Geneesmiddelen’ (GGG) program of ZonMw. The GGG
program is aimed at a more rational use of pharmaceuticals
in clinical practice. Although we also received proposals
from other ZonMw programs, all proposed projects in the
dataset were drug-related. Only projects that were granted
over the period 2007–2014, and that had also actually
started, were selected. The latter was done to ensure the
quality of the included projects and budgets, since unre-
alistic budgeting may be a reason for rejection or early
cancellation.
2.2 Classifying the Studies
For all project proposals in the initial selection, the type
of study was assessed, alongside some general charac-
teristics, such as title and date of submission. Existing
classifications [13, 14] were adapted to our specific set-
ting, leaving seven possible study types (see Fig. 1):
qualitative, observational cross-sectional, randomized
controlled, non-randomized controlled, observational
longitudinal, literature review, and data synthesis. Note
that as we considered the two types of observational
cross-sectional studies (descriptive and analytical) to be
comparable with respect to costs, we merged these into
one study type. The classification focused on designs
using empirical data (either primary data gathering or
reanalysis of secondary data) since that is the type of
study considered when ‘additional research’ is at stake in
a VOI analysis. Initially, for a subset of 21 proposals,
study type was assessed by two reviewers (any combi-
nation of TF, MJ, MA, MP, PV, IL-L, BR, ICR and
TA), and cases of disagreement were discussed until
consensus was reached. This process aimed to create
uniformity in interpretation of the heterogeneous study
designs. Subsequently, the remainder of the proposals
was assessed by a single reviewer (PV, ICR, TA, IL-L
or BR). Proposals could consist of more than one study
type.
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2.3 Data Extraction
For each study type, an exhaustive list of possible cost
drivers was drafted. Cost drivers were defined as those
variables that, according to the authors, could possibly
contribute to the costs of performing the proposed research.
Although many cost drivers were quite generic for all study
types, there were also cost drivers thought to be unique for
a certain study type; therefore, the lists differed between
study types.
The resulting sets of potential cost drivers were sent to
an expert panel (n = 5) for feedback and adjusted
accordingly. Three of the experts (all professors with a
background in pharmaceutical sciences) were members of
the review committee of the ZonMw GGG program, and,
in that capacity, they regularly need to evaluate research
proposals, including the accompanying budgets. The
remaining two experts were a pharmacoeconomics advisor
from the National Health Care Institute (Zorginstituut
Nederland; ZiN) and a program manager from ZonMw.
The outcomes were also presented at two ZonMw com-
mittee meetings (i.e. GGG and DO—Healthcare Effi-
ciency) and commented on by experts present at these
meetings. Members had been sent the study results in
advance of the meeting.
Next to potential cost drivers and study type, study costs
were extracted from the proposal budgets. An important
distinction here was between budgets requested for grant-
ing by ZonMw and any co-financing incorporated. When
part of the budget was obtained elsewhere, which is a
requirement in some of the ZonMw programs, this part is
said to be paid by co-financing. Co-financing can take
many forms, e.g. sponsoring of study medication by
industry, time contribution of staff from the research
institute, or grants from other sources. However, even
though this part of study costs was not paid for by ZonMw,
Fig. 1 Classification of studies. RCT randomized controlled trial
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it is still part of the actual costs of performing the research,
which is what we were interested in. Therefore, study costs
were considered to consist of the total sum of grants
requested plus co-financing.
Data on all possible cost drivers were extracted by PV,
ICR, TA, IL-L and BR, for a subset of the proposals. Con-
sistency was ensured by performing double extraction for
proposals that were identified as complex, and calculating
the percentage of agreement for each variable, where
agreement would be either 0 (for different values) or 1 (for
identical values). All differences between reviewers in these
proposals were investigated and, when necessary, revisions
were made to the variables. For instance, to express the fact
that an item was not present, one reviewer used ‘0’, while
another reviewer used ‘no’. This would show up as a dis-
agreement, and therefore we would revise all ‘no’ to ‘0’.
When variables, even after revision, showed poor agreement
(\ 50%), they were excluded from further analyses. See
appendix A for a detailed overview of the agreement per
variable. Where necessary, costs were adjusted to the price
level of January 1st 2014, using the general price index as
suggested by the Dutch costing manual [15].
2.4 Data Analysis
Descriptive statistics were explored and univariate regres-
sion analyses were performed based on the dataset of
extracted studies, relating costs to relevant predictors from
the list of cost drivers. The predictors investigated were
study type, number of substudies, sample size, expensive
testing, multicenter versus monocenter, study duration,
year of submission, Health Technology Assessment (HTA)
included, and whether a study was part of the GGG pro-
gram or not. This was done for all study types in combi-
nation, and for RCTs separately, since RCTs usually follow
a rather standard design and were therefore thought to
show a more straightforward relation between cost drivers
and budget. Furthermore, additional information regarding
program-specific restrictions, most importantly maximum
budgets, was obtained and was used to find out whether
these restrictions, rather than costs drivers, could explain
actual budgets. Multivariate analyses were planned to be
performed using statistically significant cost predictors
from the univariate analyses.
2.5 Costing Tool
Based on the information obtained in the previous steps, an
electronic costing tool was developed.
The tool was intended to link costs to type and size of
study, and distinguish fixed costs (only dependent on the
type of study) and variable costs (dependent on several size
parameters).
3 Results
3.1 Study Types
From the 133 original proposals obtained from ZonMw,
four were excluded, because for one proposal, the proposal
document was missing, and three proposals were dupli-
cates. Table 1 presents the number of studies per study
type. A single project could contain multiple substudies;
the proposal may, for instance, plan a literature review
followed by an RCT, and, in addition, a qualitative study;
therefore, the numbers do add up to more than 129. In total,
46 proposals contained two or more study types, while 83
proposals contained a single study type. Due to budget
constraints, we were unable to extract data from all studies.
Thus, since some of the study types were overrepresented
in the initial selection of proposals, the subset for data
extraction consisted of a subset of the RCT and longitu-
dinal observational projects, plus the complete set of the
other study types (see Table 1, third column). Selection of
RCTs and longitudinal observational studies was per-
formed randomly, apart from RCTs and longitudinal
studies that contained multiple substudies, since these
would be kept in the sample anyway because removing a
qualitative study, for instance, was not an option. Final sets
of cost drivers as used in the data extraction phase are
available in Appendix B.
Average study duration was 34 months (standard devi-
ation [SD] 9 months), and mean sample size for those
studies that included subjects (n = 63) was 642 (SD 830).
3.2 Study Costs
Table 2 summarizes the main results regarding study costs.
Total study duration was, on average, 34 months, and
budgeted costs were, on average, €475,000 (including an
average co-financing of €109,000), with a median value of
€431,000. Costs ranged from €63,000 to €1.5 million.
Figure 2 shows the distribution of costs in a histogram.
Costs per study type were analyzed in four categories,
i.e. controlled, cross-sectional, longitudinal, and other (see
Appendix C). Univariate regression analysis showed that at
the 5% statistical significance level, only the longitudinal
observational study type added significantly to total budget,
while proposals including a controlled study (either ran-
domized or non-randomized) were significantly more
expensive at the 10% level. Median costs for proposals
including an RCT (n = 35) were €482,000, compared with
€447,000 for proposals including a longitudinal observa-
tional study (n = 24), and €343,000 for all other proposals
(i.e. all proposals not including either of these, n = 15).
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3.3 Relation Between Costs and Cost Drivers
Predictor variables (cost drivers) were not statistically
significant (at the 5% level) in most univariate regression
analyses (see Appendix D and Figs. 1–5 in Appendix E).
Only study duration and GGG showed a significant relation
to costs (see Fig. 3). In the case of study duration, the
relation was positive, i.e. the longer the study duration, the
higher the costs. For GGG, the coefficient was negative,
and since yes/no was coded 1/0, this implies that GGG
studies in general have lower budgets. Multivariate
regression analysis (see Appendix C and D) confirmed the
relation between study duration and total budget in the
complete sample, but not in the sample with RCTs only. As
for study types, longitudinal designs seem to be the most
expensive, but this was not reproduced in the larger mul-
tivariate analysis including a wider range of covariates. No
other significant associations were found.
3.4 Relation Between Cost and Program
Restrictions
Figure 4 depicts the different programs and their restric-
tions regarding maximum budget and co-financing in
relation to proposal budgets. Also in this case, a clear
relation could not be found.
3.5 Choice of Costing Tool
Due to a lack of patterns in the observed data, a more
modest aim of providing reference values was set for the
tool and it was adjusted accordingly. Only items with
sufficient agreement (i.e. C 50%) were selected, as speci-
fied above. After discussion with the expert panel, items
relating to Good Clinical Practice (CGP) requirements
were dropped. Initially, studies that needed to comply with
GCP requirements were expected to be expensive because
of, for instance, the costs of monitoring. However, based
on the project proposal, whether or not a study would be
subject to GCP requirements turned out to be quite difficult
to assess, and agreement on this variable was poor.
Appendix F gives a screenshot of the input and output
frames of the costing tool. For each item, the user can
select to use it as a selection criterion and, if so, which
value should be selected. Since the more selection criteria,
the smaller the set of relevant studies, the user is warned
once selection criteria are set too tight and less than five
studies remain for comparison. Warnings also appear about
the number of studies with missing values on an outcome.
Table 1 Number of studies, and study duration, per study type
Type of study No. of studies in the initial
dataset (no. of single-type studies)
No. of studies in
data extraction
Mean study duration (SD) in months,
based on only single-type studies
1 Qualitative research 7 (0) 7 NA
2 Cross sectional observational research 10 (2) 10 30.00 (8.49)
3 RCT 80 (24) 35 36.25 (9.61)
4 Controlled study, non-randomized 6 (3) 6 28.00 (18.33)
5 Longitudinal observational research 37 (8) 24 36.00 (10.64)
6 Literature review 7 (0) 7 NA
7 Data synthesis 29 (2) 29 30.00 (8.49)
SD standard deviation, NA not applicable, RCT randomized controlled trial
Table 2 Overview of study
costsa
N Minimum 25th percentile Median 75th percentile Maximum
Total budgetb 74 €63,000 €318,000 €431,000 €557,000 €1,508,000
Total personnel costsb 74 €49,000 €200,000 €317,000 €464,000 €824,000
Co-financing budgetedb 74 €0 €0 €55,000 €175,000 €769,000
Percentage co-financing 74 0% 0% 16% 45% 73%
Total FTE 67 1.00 2.88 5.00 7.00 13.30
No. of substudies 74 1 1 1 2 4
Costs per patient 62 €30 €595 €1259 €2948 €42,304
FTE full-time equivalent
aResults within a column do not necessarily refer to the same study
bRounded to the nearest €1000
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When there are sufficient studies for comparison, the tool
returns the median total budget (as well as, for example,
median budget for personnel and amount of co-financing)
for comparable studies, based on the chosen criteria. The
tool also provides minimum and maximum and 25th and
75th percentiles. In this way, the tool can be used to pro-
vide reference values for use in a VOI, and can also be used
to support grant application reviewers.
4 Discussion
Costs for actual health services research, as subsidized by
the national organization for health research and develop-
ment in The Netherlands, ranged from €63,000 to more
than €1,500,000, with a mean of €475,000. Study costs
showed little relation to obvious explanatory variables such
as sample size, expensive testing, or number of study
locations. The only relation that was consistently statisti-
cally significant was for study duration
Overall study costs showed a wide variety, with seem-
ingly similar studies being costed very differently. Various
explanations can be offered. First, program restrictions
may have been an incentive for researchers to apply for
more costs than actually needed since they tend to try
obtaining the highest possible funding, rather than what is
needed. On the other hand, applicants may skimp on per-
sonnel and materials, for instance, of an otherwise expen-
sive clinical trial, to fit the maximum allowed budget.
While auditing precludes profits to be made on public
funding, losses are in no way prohibited, and are known to
occur in practice, and by scaling up the budget researchers
try to avoid a negative financial result after the project.
However, Fig. 4 did not convincingly show clustering of
budgets towards the maximum budget of the programs.
Moreover, the GGG program, which has no maximum
budget restrictions, tended to result in lower budgets.
Second, researchers may be poor budgeters, since their
expertise is in other fields and, as discussed above, con-
sequences of miscalculations are often found in overwork
Fig. 2 Histogram of total budget for all 129 studies
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Fig. 3 Boxplot for study
duration versus total budget
(n = 74)
Fig. 4 Total budget per ZonMw program (program name, percentage
of co-financing required, maximum budget excluding co-financing).
DO Doelmatigheids Onderzoek, HTA Health Technology Assessment
methodology research, GGG Goed Gebruik Geneesmiddelen, DO FT
Doelmatigheidsonderzoek Farmacotherapie, DO E&K Doelmatighei-
dsonderzoek Effecten & Kosten, DO VEMI Doelmatigheidsonderzoek
Vroege Evaluatie Medische Interventies, max maximum
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or co-financing from within the institute. Third, institu-
tional rules regarding overhead and additional material
costs may vary within The Netherlands.
Co-financing was another highly variable item. It was
impossible to verify whether these budgeted amounts were
actually obtained and used during the study. Finally, it was
worrisome that many proposals showed different versions
of the budget within the same proposal, which indicates
this is not an issue that is reviewed very scrupulously in the
current procedure.
Another striking finding was the large number of ‘not
reported’ elements/items in our dataset (see Appendix A
for an overview per variable). This implies that we were
unable to extract information from the grant proposals on
many items that we and our expert panel considered rele-
vant for study costs a priori, such as hours or full-time
equivalent of personnel needed, follow-up time, or total
study duration. Since these items also seem quite relevant
for a clear description of the study design in general, that is
rather surprising.
The classification of the studies turned out to be feasible,
and consistency between different researchers was satis-
factory. It was however a complicating factor that many
proposals (46 of 129) had more than one study type, and
hence budgets could not be simply allocated to a single
study design. For the application in VOI in particular,
extension with more single studies would be desirable.
The one factor that consistently came out significantly
affecting costs was study duration, or approximations
thereof. In the regression on study designs, the longitudinal
studies were shown to be more expensive; however, this
may also be related to study duration. It should be kept in
mind that a Dutch PhD lasts between 36 and 48 months,
which probably affects average study duration.
The small number of significant cost predictors could
be attributed to a lack of power. This will certainly be an
explanation for many of the more study-type-specific cost
items, such as type of post-processing for qualitative data,
or type of model in the case of data synthesis. However, a
number of cost items were extracted for almost all study
types, e.g. sample size, number of study locations, whe-
ther or not expensive tests were involved, and whether or
not a cost-effectiveness analysis was performed, and none
of these showed significance either. For variables such as
sample size, a clear relation would have been expected a
priori, but our findings did not support this expectation.
Given the current data, we do not expect that adding more
studies would result in a significant relation between
sample size and study costs. For good costing of drug
studies that have to fulfill GCP requirements, other
datasets would be needed, including more industry-sup-
ported studies. On the other hand, as the current sample
size did not allow for investigation of interactions
between sample size and, for instance, study type or study
duration, we cannot rule out the existence of these
interactions, and adding more data could contribute to
their detection.
A drawback of a tool based on historical data may be
that past mistakes will translate into future errors. If many
researchers underbudgeted their studies in the past, this will
imply a burden to future study proposals when committees
apply the historic reference values. On the other hand, no
clear reason exists why we would expect such underbud-
geting, except for anecdotal evidence. To evaluate whether
budgets were accurate, it would be useful to incorporate
information on the financial results of the projects, and also
on feasibility in retrospect, e.g. to what extent projects
were successful in recruiting the number of patients aimed
for, and whether the project finished on time or needed to
apply for an extension. Although recruitment numbers and
extensions could be traced from the final project report, the
financial settlement will not reflect the true issues with the
budget. For instance, when the budget turns out to be too
low, researchers will solve this by adding funds from their
own department, or by deploying unpaid labor. These
rather common solutions for financial and organizational
problems will rarely be recorded officially. Because of this,
the accuracy of the budget for past projects is difficult to
assess. Another limitation of this study was that as the tool
was developed using only proposals on drug-related stud-
ies, results from the tool may not be generalizable to non-
drug research.
5 Conclusions
Summarizing, we conclude that the current tool should be
considered as a work in progress that gains in value once
more studies are added to it. Of note, our tool is not pre-
dictive, but rather shows what actual budgeted costs were
for various types of studies performed in a Dutch academic
setting over the past period. We certainly do not advocate
to have the tool replace proper budgeting and the thorough
assessment of presented budgets. Nevertheless, our present
findings can be helpful to ZonMw, as well as ZonMw
committees, to evaluate their current reviewing process
with regard to study costs. For use in VOI analyses, it
would be desirable to add more single-type studies. For the
time being, the data may at least provide a better estimate
than the very simplistic assumptions that have been applied
up to now.
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